Journal
CEPHALALGIA
Volume 32, Issue 2, Pages 140-149Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0333102411431333
Keywords
PACAP38; dilatation; middle; meningeal; artery; headache
Categories
Funding
- Lundbeck Foundation as part of the Lundbeck Foundation Centre for Neurovascular Signalling (LUCENS)
- Danish Agency of Science and Innovation (FIST)
- Allergan Inc
- AstraZeneca Pharmaceuticals LP
- Boehringer Ingelheim
- Eli Lilly
- GlaxoSmithKline
- Janssen Pharmaceutical Products
- Lundbeck
- Merck
- Pfizer
Ask authors/readers for more resources
Aim: To explore a possible relationship between vasodilatation and delayed headache we examined the effect of pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) on the middle meningeal artery (MMA) and middle cerebral artery (MCA) using high resolution magnetic resonance angiography (MRA). Methods: In a double-blind, randomized, placebo-controlled study 14 healthy volunteers were scanned repeatedly after infusion (20 min) of 10 pmol/kg/min PACAP38 or placebo. In addition, four participants were scanned following subcutaneous sumatriptan (6 mg). Results: We found significant dilatation of the MMA (p = 0.00001), but not of the MCA (p = 0.50) after PACAP38. There was no change after placebo (p > 0.40). Vasodilatation (range 16-23%) lasted more than 5 h. Sumatriptan selectively contracted the MMA by 12.3% (p = 0.043). Conclusion: PACAP38-induced headache is associated with prolonged dilatation of the MMA but not of the MCA. Sumatriptan relieves headache in parallel with contraction of the MMA but not of the MCA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available